Oxymetazoline ophthalmic solution versus naphazoline solution in non-infectious conjunctivitis.
A double-blind, randomized study was carried out in 38 adult patients with non-infectious conjunctivitis to compare the efficacy and tolerance of oxymetazoline (0.025%) ophthalmic solution with that of naphazoline (0.04%) solution. Treatment was continued for 7 to 8 days and severity of symptoms was recorded before, during and at the end of therapy. At the end of the study period, 11 (69%) of 16 patients treated with oxymetazoline demonstrated a good to excellent response to therapy compared with 8 (53%) of 15 patients in the naphazoline-treated group. A statistically significant difference favouring oxymetazoline was observed in duration of action and the mean number of applications needed. No adverse reactions were reported in either treatment group.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003231:Conjunctivitis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009278:Naphazoline / Q000627:therapeutic use*; D009883:Ophthalmic Solutions; D010109:Oxymetazoline / Q000627:therapeutic use*
D007093:Imidazoles; D009883:Ophthalmic Solutions; D010109:Oxymetazoline; D009278:Naphazoline